Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
01 April 2019 | Story Leonie Bolleurs | Photo Sonia Small
Summer School
Perspectives on aquatic biomonitoring from Germany and Southern Africa were discussed at the recent German-Southern African Summer School 2019.

Water is a basic resource upon which communities rely for their health, well-being, and economic development and growth. Many countries struggle with the negative consequences of poor surface-water quality, which may threaten their food security and livelihoods.

The Centre for Environmental Management at the University of the Free State recently co-presented the German-Southern African Summer School 2019 with the Dresden University, Germany, on its Bloemfontein Campus. 

Discussions at the Summer School – attended by 66 delegates from Germany and Southern Africa – mainly focused on aquatic biomonitoring and included perspectives from Germany and Southern Africa. 

Questions such as ‘How to improve water quality?’ and ‘What about the impact of the catchment area, land use, and agriculture on water quality?’ were discussed. 

According to Marinda Avenant, Lecturer in the Centre for Environmental Management, a two-pronged approach is often used: first, ecosystem-based biomonitoring, and second, specialised water quality and toxicity-assessment methods applied at specific sites in order to identify problems.

Presenters from academia, government authorities, and the private sector shared theoretical concepts and practical experiences of establishing aquatic biomonitoring networks in Germany, South Africa, Namibia, Lesotho, Eswatini (Swaziland), and Zambia. 

The Summer School focused on an integrated approach, including catchment processes, hydrology, geomorphology, and land use, as well as chemical and biological monitoring. 

Delegates also undertook a field trip to Mokala National Park for a practical demonstration of water-quality monitoring as part of the programme. 

The Volkswagen Foundation (Germany) funded the Summer School.


News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept